心血管疾病与诊断

 Theme: Join the Health fight to treat your Heart right

August 23-24, 2020 | Madrid, Spain

Journal: Clinical & Experimental Cardiology

After the successful completion "34th World Congress on Heart Diseases” which was held amid July 27-28, 2020. We are grateful to call you to “35th World Congress on Heart Diseases”. The Heart congress is scheduled to happen on August 23-24, 2020 at the beautiful city of Madrid, Spain. This Heart Congress 2021 conference will give you an exemplary experience and enormous ideas in the research field. The perspective of the Heart conference is to establish Heart research works for people to understand how the treatment techniques get advanced and how the field get emerged in recent years. The sessions to be discussed in the conference includes Heart Disease & Failure, Cardiac and Cardiovascular Research, Diabetes, Obesity & Stroke, Pediatric Cardiology, Cardiovascular Disease , Women’s Cardiology, Nuclear Cardiology, Angiography & Intervention, Molecular Cardiology, Cardiologists, Vascular Biology, Hypertension, Cardiac Nursing, Heart Regeneration.

The expected participants to attend the conference are Academic Scientists, Business Entrepreneurs, Doctors, Clinical Experts, Cardio surgeons, Cardiologists, Directors/Managers/CEO’s, Nurses, Cardio Training Institutes, Cardio Equipment Management, Cardio Technicians, Health Care Associations, Industry Professionals, Marketing, Advertising and Promotion Agency Executives, Medical Colleges, Presidents & Vice Presidents, Research Faculty, Students.

Notable plenary presentations: Gary L Murray, The Heart and Vascular Institute, USA, Carola Y. Förster, University of Wurzburg, Germany, Aris Lacis Children’s, Clinical University Hospital, Latvia, Punitha Arasaratnam, Ng Teng Fong General Hospital, Singapur, Hong Ju Shin, Korea University Ansan Hospital, South Korea, Jacob Ostrowsky, Rainbow Babies & Children’s Hospital, USA, Mary Shibuya, Gunma University, Japan, Jeko Madjarov, Carolinas Healthcare System Pineville, USA, Michiaki Nagai, Hiroshima City Asa Hospital, Japan, Dr Filip Gemmel, Belgium, William J. Rowe, United States.

The people who have missed attending the past Heart Congress 2020 are most welcome to present your research ideas in Heart Congress 2021 conference. This conference will help you to improve networking with the eminent people in the Cardiology field.

Our organizing committee members would like to invite all the potential Cardiology people to participate in the Cardio-science and Cardiology conference to develop and enhance the field of Cardio-science.

The conference has lots of scientific sessions, workshops, Oral presentation, poster presentation, video presentation, etc.

Make your footprint in the Heart 2021 conference to explore the research and treatment techniques in Cardio-science at Paris, France.

Contact Details: Emma Parker

Program Director | Heart Congress 2020

E: heartcongress@medicalscienceconference.com

W: +447460854031

The ANS has a profound influence on the development and progression of the major cardiovascular diseases hypertension (HTN), coronary artery disease (CAD), congestive heart failure (CHF), neurogenic orthostatic hypotension (NOH), and is a major factor in sudden cardiac death (SCD) of Type 2 Diabetics (DM II). New technology, the 3.0 ANX AUTONOMIC MONITOR (Physio PT, Atlanta, GA USA), has, for the first time, provided accurate measurement of parasympathetic (P) and sympathetic (S) activity, whose sum equals heart rate variability(HRV), that is easily, quickly acquired in either an office or hospital setting. This article reviews our studies that suggest pharmacologic therapies of P and S abnormalities which reduce mortality and morbidity of these illnesses. How this new technology differs from all previous methods of HRV measurement and can be used in the daily practice of cardiology is also explained.

INTRODUCTION

In the 2^nd century A.D., Wang Shu Ho stated, “If the heartbeat gets as regular as the knocking of the woodpecker or the dripping of the rain on the roof, the patient will die within 4 days”. One century ago, the critical role of the ANS in health and disease was prophesized. In 1990, HRV (HRV = S + P) was 1^st used in clinical cardiology, emphasizing reduced HRV is associated with a poor prognosis in all major cardiovascular diseases. In 2000, HRV was included in SCD risk stratification. High S and critically low P are associated with life-threatening ventricular arrhythmias, congestive heart failure (CHF), and acute coronary syndromes (ACSs). However, ANS testing is very rarely used in today’s patient management. Why not?

Until recently, ANS measurement in the frequency domain yielded only total ANS activity, resulting assumptions and approximations of the independent contributions of S and P to total HRV. Since HRV = S + P, both must be accurately identified mathmatically. Furthermore, once in possession of this inaccurate S and P information, what were we told to do with it? So we needed accurate information and knowledge of S and P application to patient management in order to utilize this powerful tool.

ACCURATE MEASUREMENT OF S AND P

  A technologic breakthrough was developed, validated, and verified by the 1^st joint Bio-Medical Engineering program group from Massachusetts Institute of Technology and Harvard [1-5], and is now available for user-friendly routine clinical use.  It is P&S Monitoring using the ANX 3.0 MONITOR(Physio PT, Atlanta, GA USA)=. The breakthrough quantifies the independent contributions of S and P to total HRV through two simultaneous measurements:  (1) ECG monitoring which establishes total HRV (Low Frequency area [0.04-0.15 Hz] under the HR time-frequency spectral curve), simultaneously with (2) Impedance Plethysmography which independently quantitates P (a 0.12 Hz-wide window area under the HRV spectral curve centered on the modal peak of the time-frequency Respiratory Activity (RA) spectral curve; HRV due to RA is solely P-dependent). Therefore, S = HRV – P; where P is no longer assumed to be the area under the curve between 0.15-0.40 Hz, but now is quantitatively measured as the Respiratory Frequency area. The curves are analyzed using continuous wavelet transforms rather than the frequency-only fast Fourier transforms.  The latter, although accurate for stationary signals, compromises time and frequency resolution due to the fixed length windows used in analysis.

In this highly engaging and exciting talk, Roberto shares his experiences of working as an applied performance consultant with some of the biggest names in the sport. Using evidenced-based underpinning, Roberto combines the research with over three decades of applied experience working at the cutting edge of the elite-level sport.

How can you help an individual struggling in their sport to become World No.1? Helping create Olympic and world champions, medalists from a variety of diverse sports, turn around the fortunes of struggling Premier League football teams? And at the same time help increase well-being, resilience and life satisfaction? Drawing upon his experiences in cognitive behavioural therapy and Solution Focussed Therapy, Robert shares six key areas that have helped transform clients mindsets.

Biography

Roberto Forzoni is one of the world’s leading and most experienced performance consultants and has had the privilege to work with some of the biggest and most successful organisations and sports teams and individuals in the world. He has a unique background helping elite teams managers and performers reach quite extraordinary heights. His client list reads like a who’s who of high-performers, having worked with World and Olympic Champions, as well as numerous medal-performing athletes in many sports.

After completing his MSc at Brunel University, Roberto was invited to lead to MSc and a BSc level psychology module whilst at the same time taking on a variety of roles within his consultancy practice. He became the National Performance Psychology Manager for the LTA and was a Football Association tutor, writing the FA Guide to Psychhology in football.

Roberto is the founder and CEO of MYND, an evidenced-based digital audio personal development app. He can help your organisation perform better whilst at the same time increasing staff and management well-being and life and work satisfaction and as a by-product, helping with staff retention and loyalty.
 

In the time of pandemic, infectious diseases are the latest trend. Hydatid disease is one of those infectious diseases, which is caused by tapeworms. It is spread by food eaten, water, or by close contact with infected animals. The disease is still present in different parts of the world and currently affects about one million people. According to the literature, the economic cost of the disease is estimated to be around three billion US dollars a year. When hydatid disease is in humans, cysts are in the liver (in 75% of cases), the lungs (in 5–15% of cases) and other organs such as the spleen, brain, heart, and kidneys (in 10–20% of cases).

Cardiac hydatid cysts are really rare. It is not a straightforward disease that can be diagnosed like any other. The course of symptoms is vague. It might even be without any symptoms at all, while in other patients it can be fatal. Symptoms can vary from chest pain to a cough. Several cases can include small cysts all over the heart, or one large cyst in one of the heart cavities. There is no room for routine cases in such operations.

Surgical excision is done under cardiopulmonary bypass in almost all cases. However, there have been some experience with excision on a beating heart. The main fear is reinfestation. Albendazole is one important aspect of the follow-up protocol. Preserving the heart valve functions can be a real surgical challenge in some cases.

Syria is still one of those countries where hydatid disease is still present. We see many cases that are useful to enrich the literature, while there are not many similar studies in the developed countries. We are submitting the manuscript not only to talk about those rare cases, but also to improve surgical care of cardiac surgery patients in both the developed and developing countries.

Introduction: Cardiovascular diseases are numerous diseases that affect the heart. Stress and anxiety play an important role in the development of cardiovascular disease.

Purpose: The purpose of this study is to delve into the impact of anxiety disorders on the progress of heart disease.

Review Method: A bibliographic search was conducted through Medical Literature Analysis and Retrieval System Online and "Google Scholar" search engine using the keywords: anxiety disorders, anxiety, heart disease, and treatment, for the time period 2008-2020. The language except for English and Greek was the exclusion criterion for the study.

Results: Anxiety provoking situations create inflammation capable of causing heart disease of any kind since adrenaline, the hormone secreted in a moment of stress, is capable of destroying the heart. An individual's reaction to acute stress depends on the particular characteristics of his personality. The risk of stress is just as significant as hypertension, obesity and other factors regarding the development of cardiovascular diseases. Panic disorders cause heart problems and phobic disorders contribute to cardiac arrhythmias. Chronic stress also increases people’s susceptibility to heart diseases. Additionally, traumatic stress that men sometimes experience in the military can lead to heart disease. After all, personality type A, and especially hostility, is an important risk factor for developing heart disease. Moreover, the type D personality is related to heart disease. These individuals are pessimistic, anxious and isolated, avoiding social contact. It is also noted that treating anxiety disorders could reduce the risk of developing heart diseases.

Conclusions: Anxiety disorders predict a future onset of heart disease while anxious people are more at risk for developing coronary heart diseases.

Introduction: It seems there are changes in the structure and function of the myocardium in diabetic cardiomyopathy associated with diabetes mellitus. They are not directly attributable to other related factors such as coronary heart disease or hypertension.

Purpose: The purpose of this study is to search and find the impact of diabetes mellitus on the incidence of heart disease, such as cardiomyopathy and its treatment.

Review Method: A bibliographic search was conducted through "Medline" database and "Google Scholar" search engine using the keywords: diabetes, heart disease, cardiomyopathy, for the time period 2010-2020. The language except for English and Greek was the exclusion criterion for the study.

Results: Diabetic cardiomyopathy is characterized by diastolic dysfunction and myocardial ischemia, which is due to hyperglycaemia and insulin resistance causing left ventricular hypertrophy. Risk factors also include long-term alcohol abuse, smoking, hypertension, heart diseases such as sarcoidosis, and family history. The treatment aims for properly regulating diabetes, treating its symptoms, controlling risk factors for the disease and preventing it from getting worse. Regular exercise could reduce several risk factors for heart disease and improve glycemic control along with medication. Smoking must also be stopped. Finally, a healthy diet, low in fatty acids sugar and salt, and weight control within the desired range, is vital.

Conclusions: Lifestyle changes and eating habits play an important role in as regards the treatment of both diabetes and diabetic cardiomyopathy.

The ANS has a profound influence on the development and progression of the major cardiovascular diseases hypertension (HTN), coronary artery disease (CAD), congestive heart failure (CHF), neurogenic orthostatic hypotension (NOH), and is a major factor in sudden cardiac death (SCD) of Type 2 Diabetics (DM II). New technology, the 3.0 ANX AUTONOMIC MONITOR (Physio PT, Atlanta, GA USA), has, for the first time, provided accurate measurement of parasympathetic (P) and sympathetic (S) activity, whose sum equals heart rate variability(HRV), that is easily, quickly acquired in either an office or hospital setting. This article reviews our studies that suggest pharmacologic therapies of P and S abnormalities which reduce mortality and morbidity of these illnesses. How this new technology differs from all previous methods of HRV measurement and can be used in the daily practice of cardiology is also explained.

INTRODUCTION

In the 2^nd century A.D., Wang Shu Ho stated, “If the heartbeat gets as regular as the knocking of the woodpecker or the dripping of the rain on the roof, the patient will die within 4 days”. One century ago, the critical role of the ANS in health and disease was prophesized. In 1990, HRV (HRV = S + P) was 1^st used in clinical cardiology, emphasizing reduced HRV is associated with a poor prognosis in all major cardiovascular diseases. In 2000, HRV was included in SCD risk stratification. High S and critically low P are associated with life-threatening ventricular arrhythmias, congestive heart failure (CHF), and acute coronary syndromes (ACSs). However, ANS testing is very rarely used in today’s patient management. Why not?

Until recently, ANS measurement in the frequency domain yielded only total ANS activity, resulting assumptions and approximations of the independent contributions of S and P to total HRV. Since HRV = S + P, both must be accurately identified mathmatically. Furthermore, once in possession of this inaccurate S and P information, what were we told to do with it? So we needed accurate information and knowledge of S and P application to patient management in order to utilize this powerful tool.

ACCURATE MEASUREMENT OF S AND P

  A technologic breakthrough was developed, validated, and verified by the 1^st joint Bio-Medical Engineering program group from Massachusetts Institute of Technology and Harvard [1-5], and is now available for user-friendly routine clinical use.  It is P&S Monitoring using the ANX 3.0 MONITOR(Physio PT, Atlanta, GA USA)=. The breakthrough quantifies the independent contributions of S and P to total HRV through two simultaneous measurements:  (1) ECG monitoring which establishes total HRV (Low Frequency area [0.04-0.15 Hz] under the HR time-frequency spectral curve), simultaneously with (2) Impedance Plethysmography which independently quantitates P (a 0.12 Hz-wide window area under the HRV spectral curve centered on the modal peak of the time-frequency Respiratory Activity (RA) spectral curve; HRV due to RA is solely P-dependent). Therefore, S = HRV – P; where P is no longer assumed to be the area under the curve between 0.15-0.40 Hz, but now is quantitatively measured as the Respiratory Frequency area. The curves are analyzed using continuous wavelet transforms rather than the frequency-only fast Fourier transforms.  The latter, although accurate for stationary signals, compromises time and frequency resolution due to the fixed length windows used in analysis.

 Theme: Join the Health fight to treat your Heart right

August 23-24, 2020 | Madrid, Spain

Journal: Clinical & Experimental Cardiology

After the successful completion "34th World Congress on Heart Diseases” which was held amid July 27-28, 2020. We are grateful to call you to “35th World Congress on Heart Diseases”. The Heart congress is scheduled to happen on August 23-24, 2020 at the beautiful city of Madrid, Spain. This Heart Congress 2021 conference will give you an exemplary experience and enormous ideas in the research field. The perspective of the Heart conference is to establish Heart research works for people to understand how the treatment techniques get advanced and how the field get emerged in recent years. The sessions to be discussed in the conference includes Heart Disease & Failure, Cardiac and Cardiovascular Research, Diabetes, Obesity & Stroke, Pediatric Cardiology, Cardiovascular Disease , Women’s Cardiology, Nuclear Cardiology, Angiography & Intervention, Molecular Cardiology, Cardiologists, Vascular Biology, Hypertension, Cardiac Nursing, Heart Regeneration.

The expected participants to attend the conference are Academic Scientists, Business Entrepreneurs, Doctors, Clinical Experts, Cardio surgeons, Cardiologists, Directors/Managers/CEO’s, Nurses, Cardio Training Institutes, Cardio Equipment Management, Cardio Technicians, Health Care Associations, Industry Professionals, Marketing, Advertising and Promotion Agency Executives, Medical Colleges, Presidents & Vice Presidents, Research Faculty, Students.

Notable plenary presentations: Gary L Murray, The Heart and Vascular Institute, USA, Carola Y. Förster, University of Wurzburg, Germany, Aris Lacis Children’s, Clinical University Hospital, Latvia, Punitha Arasaratnam, Ng Teng Fong General Hospital, Singapur, Hong Ju Shin, Korea University Ansan Hospital, South Korea, Jacob Ostrowsky, Rainbow Babies & Children’s Hospital, USA, Mary Shibuya, Gunma University, Japan, Jeko Madjarov, Carolinas Healthcare System Pineville, USA, Michiaki Nagai, Hiroshima City Asa Hospital, Japan, Dr Filip Gemmel, Belgium, William J. Rowe, United States.

The people who have missed attending the past Heart Congress 2020 are most welcome to present your research ideas in Heart Congress 2021 conference. This conference will help you to improve networking with the eminent people in the Cardiology field.

Our organizing committee members would like to invite all the potential Cardiology people to participate in the Cardio-science and Cardiology conference to develop and enhance the field of Cardio-science.

The conference has lots of scientific sessions, workshops, Oral presentation, poster presentation, video presentation, etc.

Make your footprint in the Heart 2021 conference to explore the research and treatment techniques in Cardio-science at Paris, France.

Contact Details: Emma Parker

Program Director | Heart Congress 2020

E: heartcongress@medicalscienceconference.com

W: +447460854031

Atrial fibrillation